The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This stock page is the Follow view. The Build view lets your agent query NXTC owners, fund changes, insider filings, and source links through REST or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/NXTC"
Use Arkolith to show who owns NXTC, which funds added or reduced it, and which SEC filings prove each claim.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Affinity Asset Advisors, LLC | $2.6M | 242K | ▼−2.2% Reduced · −5K sh | Q1 2026 | |
| 2 | Sofinnova Investments, Inc. | $2.4M | 223K | —Held | Q1 2026 | |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | 160K | ▲New +160K sh | Q1 2026 | |
| 4 | VANGUARD GROUP INC | $1.3M | 92K | ▲+35% Added · +24K sh | Q4 2025 | |
| 5 | AWM Investment Company, Inc. | $1.2M | 117K | —Held | Q1 2026 | |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | $744K | 70K | —Held | Q1 2026 | |
| 7 | RENAISSANCE TECHNOLOGIES LLC | $647K | 61K | ▲+80% Added · +27K sh | Q1 2026 | |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $327K | 31K | ▲+34% Added · +8K sh | Q1 2026 | |
| 9 | BlackRock, Inc. | $297K | 28K | —Held | Q1 2026 | |
| 10 | Woodline Partners LP | $294K | 27K | ▲New +27K sh | Q1 2026 | |
| 11 | VANGUARD FIDUCIARY TRUST CO | $168K | 16K | ▲New +16K sh | Q1 2026 | |
| 12 | CITADEL ADVISORS LLC | $161K | 15K | ▲New +15K sh | Q1 2026 | |
| 13 | BARCLAYS PLC | $60K | 6K | —Held | Q1 2026 | |
| 14 | UBS Group AG | $4K | 338 | —Held | Q1 2026 | |
| 15 | MORGAN STANLEY | $705 | 66 | —Held | Q1 2026 | |
| 16 | JPMORGAN CHASE & CO | $587 | 61 | —Held | Q1 2026 | |
| 17 | BNP PARIBAS FINANCIAL MARKETS | $342 | 32 | —Held | Q1 2026 | |
| 18 | CITIGROUP INC | $11 | 1 | ▲New +1 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jan 30, 2026 | Guha Udayan | Chief Medical Officer | Grant (A) | 15K | $0 |
| Jan 30, 2026 | Shaw Kevin G. | Sr VP, General Counsel | Grant (A) | 8K | $0 |
| Jan 30, 2026 | Richman Michael | President & CEO, Director | Grant (A) | 38K | $0 |
| Jan 30, 2026 | Kundu Sourav | Sr VP, Dev. & Mfg. | Grant (A) | 8K | $0 |
| Jan 30, 2026 | Mayer Timothy | Chief Operating Officer | Grant (A) | 15K | $0 |
| Jan 30, 2026 | Cobourn Steven P. | Chief Financial Officer | Grant (A) | 15K | $0 |
| Jun 20, 2025 | Feigal Ellen | Director | Grant (A) | 19K | $0 |
| Jun 20, 2025 | Webster Stephen W | Director | Grant (A) | 19K | $0 |
| Jun 20, 2025 | Borgman Anne Elizabeth | Director | Grant (A) | 19K | $0 |
| Jun 20, 2025 | KABAKOFF DAVID S | Director | Grant (A) | 28K | $0 |
| Jun 20, 2025 | Jones Elaine V | Director | Grant (A) | 19K | $0 |
| Jun 20, 2025 | Houston John G | Director | Grant (A) | 19K | $0 |
| Company | Co-held by | Combined value |
|---|---|---|
| INSMED INCINSM | 4 funds | $437.8M |
| ELI LILLY & COLLY | 4 funds | $436.6M |
| NATERA INCNTRA | 4 funds | $336.3M |
| BRIDGEBIO PHARMA INCBBIO | 4 funds | $291.9M |
| BRISTOL-MYERS SQUIBB COBMY | 4 funds | $282.5M |
| VERTEX PHARMACEUTICALS INCVRTX | 4 funds | $212.4M |
| COGENT BIOSCIENCES INCCOGT | 4 funds | $210.2M |
| XENON PHARMACEUTICALS INCXENE | 4 funds | $196.5M |
| TANGO THERAPEUTICS INCTNGX | 4 funds | $191.3M |
| DEXCOM INCDXCM | 4 funds | $188.6M |
| ABBVIE INCABBV | 4 funds | $182.2M |
| VERA THERAPEUTICS INCVERA | 4 funds | $172.6M |
Ranked by how many of NXTC's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for NXTC. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.